--- title: "Entrada Therapeutics (TRDA) stock: news and investor profile" url: "https://aibio.space/companies/entrada-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Entrada Therapeutics, Inc. (NASDAQ: TRDA), United States. The directory classifies it as Biotechnology." --- TRDA Entrada Therapeutics, Inc. NASDAQ · United States # Entrada Therapeutics (TRDA) news Distress · 2025-04-29 ## [Entrada Therapeutics plans workforce reduction of about 20% to focus on Duchenne programs](https://aibio.space/news/entrada-therapeutics-plans-workforce-reduction-about-20-percent-focus/) The board approved a strategic plan on April 29, 2025 that expects about $2 million in charges, mostly severance. The company says its cash runway still reaches into the second quarter of 2027. ## Latest Entrada Therapeutics news 1. 2025-04-29 Distress [Entrada Therapeutics to cut about 20% of workforce in strategic plan](https://aibio.space/news/entrada-therapeutics-cut-about-20-percent-workforce-strategic-plan/) Entrada Therapeutics will cut about 20% of its workforce, with charges of about $2 million mostly in the second quarter of 2025. The 8-K gives the cash runway as lasting into the second quarter of 2027 in one place and into the second half of 2027 in another. ## Entrada Therapeutics at a glance - **Ticker**: TRDA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $99.3 million ### Related companies - [Altimmune](https://aibio.space/companies/altimmune/) NASDAQ: ALT - [4D Molecular Therapeutics](https://aibio.space/companies/4d-molecular-therapeutics/) NASDAQ: FDMT - [IGC Pharma](https://aibio.space/companies/igc-pharma/) AMEX: IGC - [BridgeBio Pharma](https://aibio.space/companies/bridgebio-pharma/) NASDAQ: BBIO - [IN8bio](https://aibio.space/companies/in8bio/) NASDAQ: INAB - [Alto Neuroscience](https://aibio.space/companies/alto-neuroscience/) NYSE: ANRO - [Wave Life Sciences](https://aibio.space/companies/wave-life-sciences/) NASDAQ: WVE - [Century Therapeutics](https://aibio.space/companies/century-therapeutics/) NASDAQ: IPSC ### Also on NASDAQ - [Biofrontera](https://aibio.space/companies/biofrontera-bfri/) BFRI - [BeyondSpring](https://aibio.space/companies/beyondspring/) BYSI - [Fulgent Genetics](https://aibio.space/companies/fulgent-genetics/) FLGT - [Celldex Therapeutics](https://aibio.space/companies/celldex-therapeutics/) CLDX - [Vericel](https://aibio.space/companies/vericel/) VCEL - [NewAmsterdam Pharma Company](https://aibio.space/companies/newamsterdam-pharma-n-v/) NAMS ## What Entrada Therapeutics does Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing genetic medicines that engage intracellular targets through a proprietary endosomal escape vehicle. Its main franchise targets Duchenne muscular dystrophy (DMD) through ENTR-601 programs for exon skipping. ENTR-601-44 and ENTR-601-45 are in global Phase 1/2 trials, and an authorization was received in the United Kingdom for a Phase 1/2 study of ENTR-601-50. The company plans to submit regulatory applications for ENTR-601-51 in 2026. The partnership with Vertex Pharmaceuticals for VX-670 targets myotonic dystrophy type 1, with dosing completion anticipated in mid-2026. The company also has two ocular programs in lead optimization for inherited retinal diseases, and its first ocular clinical candidate, ENTR-801, is aimed at Usher syndrome type 2A. The text estimates that over 11,500 patients in the U.S. and Europe carry mutations amenable to its current exon skipping programs. | Product or program | What it is | Stage | |---|---|---| | ENTR-601-44 | Oligonucleotide-based exon 44 skipping therapy for Duchenne muscular dystrophy | Phase 1/2 global trial, dosing ongoing | | ENTR-601-45 | Oligonucleotide-based exon 45 skipping therapy for Duchenne muscular dystrophy | Phase 1/2 global trial, patient dosing initiated | | ENTR-601-50 | Exon 50 skipping therapy for Duchenne muscular dystrophy | Phase 1/2 study authorized in the UK | | ENTR-601-51 | Duchenne muscular dystrophy program with regulatory submissions planned | Regulatory submissions expected in 2026 | | VX-670 | Partnered with Vertex for myotonic dystrophy type 1 | Phase 1/2 global trial, MAD portion being dosed | | ENTR-801 | Ocular oligonucleotide therapy for Usher syndrome type 2A | First ocular clinical candidate | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000011/trda-20251231.htm). ## Entrada Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$25.4 million](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000011/) | [$210.8 million](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000011/) | | Research and development | [$142.3 million](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000011/) | [$125.3 million](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000011/) | | Net income (loss) | [-$143.8 million](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000011/) | [$65.6 million](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000011/) | | Cash from operations | [-$128.5 million](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000011/) | [-$41.6 million](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000011/) | | Cash and equivalents | [$90.4 million](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000054/) | [$101.2 million](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000011/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $99.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Entrada Therapeutics What is the ticker symbol of Entrada Therapeutics? Entrada Therapeutics, Inc. trades under the ticker TRDA on NASDAQ. Where is Entrada Therapeutics listed? Entrada Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Entrada Therapeutics? The SEC Central Index Key (CIK) for Entrada Therapeutics, Inc. is 1689375. Its filings are on SEC EDGAR. How many shares does Entrada Therapeutics have outstanding? 38,936,669 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is Entrada Therapeutics listed under? Our directory records Entrada Therapeutics, Inc. under United States. What does Entrada Therapeutics do? Our directory classifies Entrada Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Entrada Therapeutics? The ISIN recorded for Entrada Therapeutics, Inc. is US29384C1080. Does aibio.space cover Entrada Therapeutics? aibio.space lists Entrada Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Entrada Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Entrada Therapeutics develop? Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing genetic medicines that engage intracellular targets through a proprietary endosomal escape vehicle. Its main franchise targets Duchenne muscular dystrophy (DMD) through ENTR-601 programs for exon skipping. What is ENTR-601-44 from Entrada Therapeutics? ENTR-601-44: Oligonucleotide-based exon 44 skipping therapy for Duchenne muscular dystrophy Stage: Phase 1/2 global trial, dosing ongoing. What is ENTR-601-45 from Entrada Therapeutics? ENTR-601-45: Oligonucleotide-based exon 45 skipping therapy for Duchenne muscular dystrophy Stage: Phase 1/2 global trial, patient dosing initiated. What was Entrada Therapeutics's revenue last year? $25.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Entrada Therapeutics profitable? Entrada Therapeutics, Inc. reported a net loss of $143.8 million for the fiscal year ended Dec 31, 2025, and used $128.5 million of cash in operations, per its annual report to the SEC. How much does Entrada Therapeutics spend on research and development? $142.3 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Entrada Therapeutics Members talk about Entrada Therapeutics (TRDA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Entrada Therapeutics, newest first. Each line links the filing it comes from. 1. 2025-04-29 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). [Source](https://www.sec.gov/Archives/edgar/data/1689375/000110465925041204/tm2513421d1_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TRDA on TradingView](https://www.tradingview.com/symbols/NASDAQ-TRDA/). ## SEC filings and registration - **SEC name**: Entrada Therapeutics, Inc. - **CIK**: 1689375 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: TRDA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: ONE DESIGN CENTER PLACE, BOSTON, MA, 02210 - **Phone**: 857-305-1825 - **Shares outstanding**: 38,936,669 as of 2026-07-31 (10-Q filed 2026-08-05) - **Former names**: CycloPorters, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000057/trda-20261014.htm) filed 2026-10-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000054/trda-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000052/trda-20260805.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1689375/000110465926072326/tm2617532d1_8k.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1689375/000110465926063325/tm2614944d1_8k.htm) filed 2026-05-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000028/trda-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000027/trda-20260507.htm) filed 2026-05-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000021/trda-20260424.htm) filed 2026-04-24 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001689375), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Entrada Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TRDA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Entrada Therapeutics, Inc. - **Ticker**: TRDA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US29384C1080 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TRDA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/entrada-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Entrada Therapeutics (TRDA) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/entrada-therapeutics/